Startups

Archireef Is Turning Nature Risk Management Into a Business Priority

The Hong Kong startup combines 3D-printed reef tiles, biodiversity monitoring and long-term data to help companies manage their impact on marine ecosystems.

Updated

August 7, 2026 4:10 AM

Young corals growing on Archireef's 3D-printed terracotta reef tiles beneath the sea. IMAGE: ARCHIREFF

Anyone who has snorkeled over a coral reef has probably admired its vibrant colours and the marine life swimming between its branches. What is less visible is how easily these ecosystems can be damaged. Rising ocean temperatures and pollution continue to put reefs under pressure, while coastal development creates another threat. Construction can stir up sediment that settles on corals, blocking the sunlight they need and making it harder for damaged reefs to recover.  

Protecting marine ecosystems is becoming a shared responsibility. Alongside scientists, governments and conservation groups, businesses whose operations affect the ocean are increasingly expected to understand, manage and reduce their environmental impact. They must also show regulators, banks and investors that they are meeting their environmental commitments.  

Archireef helps businesses meet those demands. Founded by Vriko Yu, the Hong Kong-rooted B2B startup specializes in marine ecosystem restoration and ocean nature risk management. Drawing on years of research at the University of Hong Kong, Yu built the company to help organisations understand, measure and reduce their impact on marine ecosystems.  

Yu describes Archireef as an “end-to-end ocean nature risk management company”.

“What we offer them is a credible way to meet those obligations and stand behind the results,” she says.

One of the company’s main tools for restoring damaged marine ecosystems is its flagship 3D-printed terracotta reef tile. The tiles provide a stable foundation where young corals can attach, grow and survive over time.  

Archireef chose terracotta instead of concrete and other conventional materials because it is pH-neutral and does not release harmful chemicals into the water. Its surface also gives corals a suitable place to attach naturally.

Before placing a single tile in the ocean, the team studies the proposed restoration site to determine whether recovery is possible. It assesses the water quality, biodiversity and general health of the ecosystem. As Yu explains, restoration should begin only where nature has a realistic chance to recover.

“Restoration isn’t about replacing nature or engineering a reef into existence. It is about removing the barriers and giving a degraded system the conditions it needs to begin recovering on its own”, she says.

Once the team selects a site, divers carefully place the tiles on the seabed. Their curves, ridges and crevices imitate the structure of a natural coral reef, creating sheltered spaces for marine species. The design also helps limit sediment build-up, which can block sunlight and smother young corals.

A diver attaches young coral fragments to Archireef's 3D-printed terracotta reef tile. IMAGE: ARCHIREFF

Archireef adjusts the shape of its reef tiles for each project.

“There’s no universal reef, so there’s no universal tile”, Yu says.

Instead of producing one standard model, the company adapts each design to the coral species, water conditions and surrounding marine environment. A coral restoration project in Hong Kong may therefore require a different tile from one in Saudi Arabia, even when the same manufacturing process is used.

“The biggest adaptation from site to site is usually the match between design, species and environment, not the manufacturing itself ”, Yu explains.

Three common coral species found in Hong Kong, representing different growth forms and resilience. IMAGE: ARCHIREFF

Although the reef tile is Archireef’s most recognizable innovation, Yu sees it as one part of a much broader service.

“The reef tile gets the attention because it’s tangible,” she says. “But the real product is the proof — defensible, audit-ready evidence of nature recovery that an organization can put in a disclosure and stand behind under scrutiny”.

Producing that evidence requires years of biodiversity monitoring. Long after the reef tiles have been installed, Archireef continues to track coral survival and the health of the surrounding marine ecosystem. Its monitoring methods include ecological surveys, AI-assisted species recognition, photogrammetry and environmental DNA testing.

An underwater survey documents coral growth on Archireef's reef tile during long-term monitoring. IMAGE: ARCHIREFF

Photogrammetry uses photographs to produce detailed 3D models of the reef. These models allow the team to measure changes in coral growth and reef structure over time.

Environmental DNA, commonly known as eDNA, offers another way to monitor marine biodiversity. Traditional ecological surveys often depend on divers recording the species they can see. eDNA testing instead examines traces of genetic material left in the water by marine organisms, including skin cells, mucus and waste.

By analyzing these traces, Archireef can detect species that may be hidden, difficult to identify or absent during a dive. This gives the company a more complete picture of the ecosystem and how it is changing.

For Archireef, the success of a coral reef restoration project is determined by what happens several years after installation.

“The indicators that matter aren’t the ones that look good on deployment day”, Yu says. “They’re the ones that show, two, three and five years on, whether a genuine ecosystem is establishing and sustaining itself”.  

At the company’s first restoration site in Hoi Ha Wan, Hong Kong, around 90% of the transplanted corals remained alive four years after deployment. The long-term survival rate suggests that the ecosystem is recovering rather than simply appearing healthy during the early stages of the project.

Results like these have helped Archireef move beyond academic research and secure collaborations across the public and private sectors. In Hong Kong, the company has worked with government departments and public organisations responsible for coastal infrastructure and marine conservation.

Keep Reading

Hong Kong

Hong Kong AI Biotech Startup METiS TechBio Draws Major Investor Demand in IPO

METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body

Updated

May 14, 2026 3:02 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH

Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.

The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.

Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.

The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.

That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.

METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.

The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.

One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.

Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.

METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.

The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.

Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."

The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.

For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.